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Summary
Background: Opioid dependence is common amongst the prison population, with increased risk of fatal overdose in 
the immediate post-release period. Aim: The study aimed to review the effectiveness of pharmacotherapies (Methadone 
(METH), Buprenorphine (BUP), levo-alpha acetyl methadol (LAAM), Naltrexone (NLT) and Naloxone (NLX)) in reduc-
ing overdose deaths and increasing treatment retention in opioid dependent prisoners on release. Methods: A systematic 
review of studies on recently discharged opioid dependent prisoners receiving METH, BUP, LAAM, NLT and/or NLX 
was conducted. Factors of interest regarded post-release treatment retention, non-fatal overdoses (NFODs), overdose 
mortality, and continued heroin and/or other illicit drug use. Searches were conducted using MESH terms; opioid related 
disorder, prisoner, NLT, NLX, METH, BUP, LAAM, overdose. Exclusion criteria were applied as per PRISMA guide-
lines. Quality, outcome and risk of bias assessments were applied across studies. Results: Eight randomised control trials 
(RCT), one non-randomised trial and five observational studies formed the data set. Agonist Opioid Treatment (AOT) 
(METH, BUP, LAAM) initiated pre-release was associated with significant post-release treatment retention on discharge 
into the community, and post-release reduction in heroin use. Prisoners on BUP or METH on discharge had significantly 
reduced mortality risks in the immediate four weeks post-release. There was insufficient evidence supporting a reduction 
in NFODs and continued other illicit drug use. Conclusions: The review underscores the need for prisoners on AOT to be 
supported with continued treatment on release into the community. Further research is warranted to investigate potential 
utility of long-acting NLT formulations and take-home NLX (THN) in pre –release opioid dependant prisoners.
Key Words: Prisoner; opioid replacement; overdose; methadone; buprenorphine; levo-alpha acetyl methadol; LAAM; 
naltrexone; naloxone; retention
1. Introduction
Opioid dependence has the greatest disease bur-
den of all illicit drugs [15] with drug overdose deaths 
a significant contributor to this burden [14]. Problem 
drug use – and in particular opioid use, dependence 
and drug injecting behaviours – is significantly more 
prevalent amongst the prison population compared to 
the general population [25, 33, 63, 68]. People who 
inject drugs (PWID) have a lifetime incarceration 
prevalence of 56% to 90% [33], with continued and 
new injecting occurring when incarcerated [1, 23, 
33]. The two week period following prison release is 
a particularly vulnerable period for overdose deaths 
[5, 57, 64, 69], mainly due to reduced tolerance to 
opioids, presence of relapse triggers, drug availabil-
ity and on-going complex medical, psychological and 
social issues among this cohort [4, 24, 57]. Risk of 
post-release overdose is increased among prisoners 
aged between 25-35 years, with a history of injecting 
drug use (IDU), male gender and a diagnosis of men-
tal illness [11, 24, 35, 69]. The tendency for prisoners 
to “celebrate” post-release may also be a contributing 
factor [57]. 
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Non-fatal overdoses (NFODs) occur more fre-
quently than fatal overdoses and are associated with 
history of recent incarceration and increased mortal-
ity and morbidity rates [13, 36]. In terms of the prison 
population, exposure to hepatitis C, ever attempting 
suicide and a history of injecting heroin and/or oth-
er opiates increase risk of NFOD [59]. Risk factors 
for NFODs in the community include homelessness, 
a history of multiple arrests and/or imprisonments, 
longer time in prison, binge drug use and/or an in-
creased frequency of injecting, street injecting, longer 
history of opiate use and poly-substance use [59; 74]. 
Marked variations in overdose deaths globally may 
reflect local differences in prison and community 
drug treatment policies, differences in drug use pat-
terns, particularly injecting and polysubstance misuse 
and the availability and purity of heroin and other 
drugs [57]. 
Structured community based drug treatment pro-
grammes (particularly the range of treatments for her-
oin dependence using pharmacotherapies, methadone 
(METH), buprenorphine (BUP), levo-alpha acetyl 
methadol (LAAM), naltrexone (NLT) and naloxone 
(NLX)), spirituality/religion and family are identified 
as being protective for preventing relapse and drug 
overdose on release [4, 12]. The provision of commu-
nity Agonist Opioid Treatment (AOT) using METH, 
BUP or LAAM is shown to increase treatment reten-
tion and reduce overdose deaths in the community [7, 
9, 36, 47, 55]. Opioid dependent patients retained in 
METH maintenance treatment (MMT) have reduced 
mortality, reduced criminality and improved health 
compared to those who are not in MMT [8, 29]. BUP 
as a combined product with NLX has reduced poten-
tial for diversion [3], and similar benefits to METH, 
being: increased treatment retention, reduced illicit 
drug use and criminal activity in the community when 
compared to placebo [47, 53]. Other treatment op-
tions include LAAM which is a longer acting opioid 
agonist, with similar or better outcomes than METH 
[9]. Concerns regarding its potential to cause cardiac 
arrhythmias (QTc prolongation effect) have contrib-
uted to its discontinuation as an AOT [49]. Sustained 
release NLT is a full opioid antagonist; by blocking 
the effects of heroin and other opioids it has shown 
in improving treatment retention, reducing heroin use 
and cravings [32, 41, 42, 49]. Lastly, take-home NLX 
(THN) has been proposed as a novel preventative 
measure to reduce the likelihood of a fatal outcome 
from heroin overdose amongst drug users [49, 69] 
with anecdotal reports of small-scale interventions 
showing some possible benefits in the community 
setting [22, 62]. 
AOT, when provided in prison, reduces the 
in-prison use of heroin, injecting and syringe shar-
ing and increases retention in post-release treatment 
when continued in the community [30]. However, its 
impact on post-release overdose rates is unclear [30]. 
In the prison setting, MMT is shown to reduce drug 
use, drug injecting, risk taking behaviour and HIV and 
hepatitis C virus (HCV) infection rates [18]. Whilst 
BUP is increasingly used in opioid dependence treat-
ment [3, 49], it has poor bioavailability and must be 
taken sublingually, a factor that impacts on ingestion 
supervision and diversion potential in a prison setting 
[53]. BUP may have relevance for the choice of AOT 
for prisoners since most post-release overdoses for 
males are heroin related and for females involve ben-
zodiazepines, cocaine and tricyclic antidepressants 
[24]. LAAM’s prolonged duration of effect may also 
have some benefits in recently released prisoners al-
lowing a greater time frame for the released prisoner 
to engage with community services before the onset 
of opioid withdrawals. NLT reduces heroin use and 
re-incarceration when compared with placebo alone 
but has no effect on reducing relapse or treatment 
retention [58]. There is evidence to support the use 
of NLT in highly motivated patients [72] and in pris-
oners on parole [11]. Outcomes are compromised by 
poor patient interest, high dropout rates and increased 
risk of overdose when the patient stops treatment, 
particularly in the first two weeks of discontinuation 
[10, 17, 60]. However, as its antagonist effect can last 
for up to six months, it affords post-release overdose 
protection during the high risk two to four week pe-
riod, allowing patients to link with community treat-
ment services [49]. Lastly, THN has potential utility 
to reduce post-release overdose if widely distributed 
among prisoners on release, their drug-taking peers, 
friends and family. 
Despite the central role of AOT in community 
based services, its availability and utilisation in pris-
ons is limited [66, 67]. The medical management of 
addiction, and in particular its management among 
prisoners, is often influenced by negative societal at-
titudes to drug users, including a failure to understand 
its chronic relapsing nature; that detoxification should 
be the most desired outcome for opioid dependent 
prisoners, and that prisons should be drug free [33, 
66]. AOT is often perceived as simply replacing one 
drug for another and encouraging illicit drug use [33]. 
Discontinuation of AOT is a common occurrence for 
those entering prison [43, 52, 66]. Developments are 
slow and hampered by ambivalence among prison of-
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ficials, doctors and staff, variation in health policies, 
difficulty in recruiting adequate numbers of suitably 
trained staff and restrictive criteria for eligibility [43, 
65]. Extant research is unclear with regard to which 
pharmacotherapies are particularly suited to the pris-
on population. Given the lack of evidence with regard 
to impact of pharmacotherapies in reducing prevent-
able overdose deaths post-prison release, and with the 
expansion of prison drug treatment services, particu-
larly in Europe, the increasing availability and use of 
long acting NLT and the rapid expansion of THN as a 
potential overdose prevention strategy, it is important 
that continued efforts to evaluate prison based phar-
macotherapies be undertaken. The aim of the system-
atic review was to review existing scientific evidence 
and evaluate if prison based pharmacotherapies when 
provided pre-release improve post-release treatment 
retention and reduce post-release overdose. 
2. Methods
A systematic review of studies on recently dis-
charged opioid dependent prisoners receiving METH, 
BUP, LAAM, NLT and/or NLX was conducted. Fac-
tors of interest regarded post-release treatment reten-
tion, NFODs, overdose mortality rates, and continued 
heroin and/or other illicit drug use. Electronic search-
es using MESH terms and conducted on the follow-
ing research databases: Cochrane Central Register of 
Controlled Trials, Medline, Embase, CINAHL and 
PsycINF0. MESH terms are presented in Table 1. 
Human studies (experimental randomised control and 
clinical trials, and observational cohort, case-control, 
and cross-sectional studies) were included with no re-
strictions placed on publication date or language. 
Retrieved records included peer reviewed pub-
lications, other scientific publications (i.e. Scientific 
Monographs) and non-peer reviewed journals and 
grey literature (technical reports, conference papers, 
unpublished thesis). Additional hand searches were 
conducted on the reference lists of all selected arti-
cles, and by contacting experts (lead authors of all the 
included studies and lead authors of the previously 
completed systematic reviews of prison drug treat-
ment and post-release overdose) (n=15) to enquire 
about their knowledge of other studies, published or 
unpublished relevant to this review. Inclusion criteria 
centred on studies reporting on prisoners with a his-
tory of opioid dependence or those deemed at risk of 
overdose on release from prison who were receiving 
AOT (METH, BUP, LAAM), NLT or a supply NLX 
at release; NLT and THN on release from prison, and 
measures relating to primary outcomes; treatment 
retention, NFODs, and overdose mortality, and sec-
ondary outcomes; continued use of heroin and other 
illicit drugs (self-reported and/or confirmed by bio-
logical markers). 
For all studies that satisfied inclusion criteria 
data was extracted in a standardized format. Data was 
extracted by author, year, location, study design, in-
tervention, study group, outcomes (primary and sec-
ondary), sample size, and follow up. A total of 357 
articles were identified in the initial search phase. Of 
these, 286 were from Medline, 58 were from PsycIN-
FO, eight from Embase and five from the Cochrane 
Central register for control trials and two additional 
articles were included from grey literature search. 
Of these 357 articles, 75 were found to be dupli-
cates and were eliminated leaving 284 articles to be 
screened by title. Of these 284 articles screened, 120 
were eliminated by title. The remaining 164 articles 
were reviewed by abstract and 140 were eliminated 
because they did not focus on the included pharmaco-
therapies and/or the primary outcomes of the system-
atic review. The final 24 articles were read in full text 
and two were excluded because the pharmacothera-
pies under review were not included, three were pre-
vious systematic reviews, one dealt with an offender 
residential unit and one dealt only with prisoner mor-
tality while incarcerated. The PRISMA flowchart is 
presented in Figure 1. 
The final 17 studies were cross-referenced 
against studies included in the previous systematic 
reviews to ensure potential studies had not been ex-
Table 1. MESH terms
Population - prison, inmate, parolee, opioid dependant, custodial, drug users, heroin users.
Intervention - overdose prevention, opioid agonist, antagonist, NLX, take home NLX, NLT, METH, BUP, 
opioid maintenance, agonist opioid treatment, LAAM.
Comparison - no treatment, other pharmacotherapy, psychosocial intervention only.
Outcome - overdose, death, mortality, treatment retention, effectiveness, drug related deaths.
METH=methadone, BUP=buprenorphine, NLX=naloxone, NLT=naltrexone, 
LAAM= levo-alpha acetyl methadol
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cluded. 11 of the 17 studies were randomised con-
trol trials (RCT)s. Of these four [27, 38-40] followed 
up the same sample of 211 patients at one, three, six 
and twelve months post-release; and were considered 
as one trial (one study entry). The remainder were 
one non randomised trial that arose from a feasibil-
ity study [75] and five observational studies. Eligible 
studies are presented in Table 2. 
Quality, outcome and risk of bias assessments 
were applied across studies. Primary and second-
ary outcomes were compared in terms of no treat-
ment versus other treatment (pharmacological or 
psychosocial), and synthesised per outcome in terms 
of number of studies reporting on each outcome with 
p values and effect sizes included (where available). 
Values of p<0.05 were considered a statistically sig-
nificant outcome. Where appropriate, risk of bias was 
conducted across studies and at specific outcome lev-
el including whether the biases were considered like-
ly to exaggerate or under-estimate any reported treat-
ment effect. The risks of bias assessment pertained to 
selection, performance, detection, attrition, reporting 
and other sources of bias [31]. 
Figure 1. PRISMA flowchart
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3. Results
3.1. Characteristics of included studies
Overall, 14 studies (nine from the US; two from 
Australia, one from Malaysia, one from Norway, and 
one from Puerto Rico) involving a total of 18,277 
individuals, 14,681 male and 3,596 females are pre-
sented in Table 3. Eight RCTs were included involv-
ing 877 individuals, 808 males and 69 females. Seven 
were from the USA and one was from Norway. One 
non-randomised trial was from the USA, involving 44 
individuals, 37 males and seven females. Five obser-
vational studies involved 17,356 individuals, 13,836 
males and 3,520 females. Two observational studies 
were from the United States (US), one from Australia, 
one from Puerto Rico and one from Malaysia. Phar-
macotherapy interventions and comparisons were as 
follows. See Table 3; 
• METH (experimental) vs. no pharmacother-
apy +/- community referral (n=6)
• LAAM vs. no pharmacotherapy+ referral 
information (n=1).
• BUP vs. no pharmacotherapy +/- commu-
nity referral (n=2)
• AOT (METH and BUP ) vs. no pharmaco-
therapy (n=1)
• NLT vs. no pharmacotherapy (n=1)
• BUP vs. METH (n= 1)
• NLT vs. METH (n=1)
• METH ≥ 80mg versus METH < 80mg (n=1).
3.2. Synthesis of primary outcomes
3.2.1. Treatment Retention 
Syntheses of results indicate that initiation of 
OSTs (METH, BUP, or LAAM) in prison prior to 
release had a significant impact on post-release treat-
ment retention. The range for METH was 69%- 86%, 
BUP was 48%- 92% and LAAM was 95%. All studies 
reporting on treatment retention as outcome showed a 
significant difference in the numbers attending com-
munity treatment immediately post-release between 
those on AOT compared with those not on AOT [20, 
27, 37, 38, 51, 56, 75]. Six of the eight studies showed 
this difference to be statistically significant (p<0.05). 
See Table Four. 
Treatment retention and days in treatment at 
three, six and twelve months follow-up were also 
better in the pre-release treatment groups [20, 27, 
37, 39, 40, 51, 75]. In studies that divided the non-
treatment control into those with a structured refer-
Table 2. Eligible Studies
Ref. No. Author, Country Date Number Intervention
RCTs/ Clinical Trials
1. Dole et al., USA 1969 Male = 32 METH
2. Kinloch et al., USA 2005 Male = 145 LAAM
3. Kinloch et al., USAGordon et al., USA
2007,2008,2009,
2008 Male = 211 METH
4. Magura et al., USA 2009 Male = 113 BUP
5. Lobmaier et al., Norway 2010 Male and female = 46 NLT
6. McKenzie et al., USA 2012 Male = 90 METH 
7. Zaller et al., USA 2013 Male and female = 44 BUP
8. Gordon et al.,USA 2014 Male and female= 213 BUP
9. Lee et al., USA 2014 Male and female = 44 NLT
Observational Studies
10. Magura et al., USA 1993 Male = 446 METH
11. Dolan et al., Australia 2005 Male = 382 METH
12. Garcia et al., Puerto Rico 2007 Male= 45 BUP
13. Wicherrsham et al., Malaysia 2013 Male = 30 METH dose
14. Degenhardt et al., Australia 2014 Male and Female = 16,453 METH and BUP (AOT)
METH=methadone, BUP=buprenorphine, NLX=naloxone, NLT=naltrexone, 
LAAM= levo-alpha acetyl methadol
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Table 3. Characteristics of Included Studies
Ref 
No. 
Study De-
sign Medication Study Group Specific Outcomes
Sam-
ple n Follow up 
1. RCT METH
Heroin depend-
ent pre-release 
prisoners (male)
Treatment retention (primary). 
Heroin use (secondary) 32 7-10 months
2. RCT LAAM
Heroin dependent 
prerelease prison-
ers (male)
Treatment entry and treatment 
retention (primary). Heroin use (self 
report)(secondary)
145 9 months
3. RCT METH
Heroin dependent 
prerelease prison-
ers (male)
Treatment entry/retention (primary). 
Mortality (primary).
Opioid urinalysis (secondary). 
Heroin use self report (secondary).
211 1, 3, 6, 12 months
4. RCT METH vs BUP
Opioid dependent 
short term prison-
ers (male)
Treatment entry (primary)
Heroin use (self report) (secondary) 133 3 months
5. RCT NLT vs METH
Pre-release 
heroin dependent 
at least 2 months 
sentence time 
remaining (male 
and female)
Treatment retention (primary). 
Drug use/ self report at 6 
months(secondary)
46 6 months
6. RCT METH
Pre-release 
opioid dependent 
prisoners (male)
Treatment retention (primary)
Non fatal overdose (primary)
Mortality (primary)
Heroin and drug use (self report) 
(secondary)
90 2 weeks 6 months
7. Feasibility- clinical trial BUP
Opioid dependent 
prisoners (male 
and female)
Treatment retention (primary) 44 6 months 
8. RCT BUP
Non opioid toler-
ant with heroin 
dependence 
histories (male 
and female)
Enter community treatment (pri-
mary) 213
10 days post-
release 
9. RCT NLT
Opioid depend 
patients not seek-
ing AOT
Opiate relapse at week 4 self report 
and urine toxicology (secondary) 29 4 week
10. Prospective cohort METH
Daily heroin us-
ers -admitted for 
short sentences 
(male)
Treatment entry/treatment retention 
(primary)
Drug use (self report) (secondary)
446 6.5 months
11. Case control METH
Opioid dependent 
prisoners in ear-
lier trial in 2003 
(male)
Mortality (primary). 382 48 months 
12. Prospective cohort BUP 
Opioid depend-
ent pre-release 
prisoners (male)
Heroin use (self report) (secondary).
Morphine drug screen (secondary). 45 1 month
13. Prospective cohort
METH
 dose
Opioid depend-
ent HIV positive 
patients (male)
Treatment retention (primary) 30 4 months
14. Retrospec-tive cohort
METH
and 
BUP
(0ST)
Opioid –de-
pendent people 
entering AOT 
and released 
form prison at 
least once during 
2000-2012 (male 
and female)
Post –prison release mortality (pri-
mary)
16, 
453
1 week, 4 
weeks, 12 
months
METH=methadone, BUP=buprenorphine, NLX=naloxone, NLT=naltrexone, 
LAAM= levo-alpha acetyl methadol
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mediate post-release retention with retention rate of 
48% for BUP and 14% for METH (p< 0.001) [53]. 
NLT had better outcomes than METH at six months 
ral post-release and those without showed better out-
comes in the structured referral group [27, 38-40]. 
BUP showed better outcomes than METH for im-
Table 4. Treatment Retention
Ref 
No. Outcome Intervention
Study 
type Outcome 
Positive 
outcome 
at p < 
0.05
Comments 
Possible 
impact of 
bias on 
treatment 
effect 
(from on 
Table 4)
1.
Treat-
ment 
retention
METH ver-
sus referral 
or no treat-
ment
RCT Experimental (75%) vs. ( 0%) control retained in treatment at 6months
Statistical 
analysis 
not done on 
outcomes
None 
3.
1 month experimental (68.6%) vs. 
control (8%) and (50%) 
3 months (69%) vs. (8%) (50%)
Number of days in treatment at 6 
months (100) vs. (14) (58) 
12 months (166) VS. (23) (91)
P= < .05 
p < 
0.0001
P< 0.0001
P<.002
Small 
sample Relatively little
6.
Experimental group (86%) vs. control 
(41%) and (22%)
Experimental group entered treatment 
within a shorter period of time (3)days 
vs. (9) and (5) days
P < 0.001
P=0.03
Small 
sample None
10. Observa-tional 
AOT in prison > entry into the commu-
nity (85%) vs. (37%) 
Treatment retention at 6 months (27%) 
vs. (9%)
P< 0.01
P< 0.01 cohort
Underesti-
mate 
2.
Treat-
ment 
retention 
LAMM 
versus no 
treatment
RCT
Immediate post-release treatment reten-
tion (95%) vs. (10%) and (8%) 
6 month retention treatment post (53 
%) vs. (0%)
P< 0.01 No analysis at 6 months Unclear
8.
Treat-
ment 
retention 
BUP versus 
no treat-
ment
RCT
48/101(47.5%) entered community 
treatment in in-prison group compared 
to 43/101 (33.7%) of counseling only 
treatment.
P= 0.01
Small 
study,
Included 
females
None
7.
Non-ran-
domised 
trial
(92%) in prison treatment vs. (78%) of 
referral outside.
 Average days to entry were (3.2) vs. 
(9.2.) 
6 month Treatment retention (83%) vs. 
(34 %.) 
Weeks retained in treatment (20) weeks 
vs. (13 ) weeks
P=0.3
P= 0.10
P=0.005
P=0.05
Non-ran-
domised.
Small num-
bers
None
12. Observa-tional
(85%) of in-prison treatment entered 
community treatment post-release.
Treatment
only None
13.
Treat-
ment 
retention 
METH dose Observa-tional
≥80mg on release, 6 month follow up 
(61.5%) vs. (21.4%), One month attri-
tion <80mg, (64%) vs. (15.4 %)
P<0.01 No p value for attrition None
4.
Treat-
ment 
retention
BUP versus 
METH RCT
BUP (48%) vs. METH (14%). 
Intended to continue treatment BUP 
(93%0) vs. METH (44%)
P<0.001
P< 0.001
Small num-
bers None
5.
Treat-
ment 
retention
NLT versus 
METH RCT
6 month NLT (69.6%) vs. METH 
(23.8%) P= 0.003
METH=methadone, BUP=buprenorphine, NLX=naloxone, NLT=naltrexone, 
LAAM= levo-alpha acetyl methadol
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month's treatment retention for those on higher doses 
(p<0.01) [71]. One observational study [51] showed 
that receiving METH in prison increased commu-
nity treatment entry compared to those not on AOT 
(85% vs. 37%) (p< 0.01) reducing significantly at six 
follow up with 70% still in treatment compared to 
24% of the METH control group (p=0.003) [50]. The 
only study reporting on METH dose showed less than 
one month's treatment attrition in those receiving 
≥80mg and a statistically significant differences in six 
Table 5. Non-Fatal Overdose (NFODs)
Ref Out-come Intervention Study type Outcome 
Positive 
outcome 
at 
p < 0.05
Comments 
Possible impact 
of bias on treat-
ment effect (from 
on Table 4)
6. NFODs METH versus no treatment RCT
8/ 62 experienced non-
fatal overdose- occurring 
across all arms.
Small num-
bers,
self report,
underestimate
7. BUP versus no treatment
Non ran-
domised 
trial
3/36 – all in the no tx pre-
release P=0.23
Small num-
bers underestimate
METH=methadone, BUP=buprenorphine, NLX=naloxone, NLT=naltrexone, 
LAAM= levo-alpha acetyl methadol
Table 6. Overdose Mortality
Ref Out-come
Interven-
tion Study type Outcome 
Positive 
outcome 
at p < 
0.05
Comments 
Possible impact of 
bias on treatment 
effect (from on 
Table 4)
3.
Over-
dose 
deaths/
mortal-
ity 
METH
versus no 
treatment
RCT
One overdose death in the 
no treatment group at one 
month, 
8 deaths at 12 months. 7 in 
the no treatment groups, 4 
overdoses and 3 others. The 
overdose death in treatment 
group was cardiovascular 
related.
Small numbers No effect
5.
No deaths at 6 months fol-
low up for 41/44 followed 
up patients
Small numbers,
Pre-treatment 
dropout
None
6.
2 died of drug overdose 
within days of release in no 
treatment control group
11. Observa-tional
17 deaths all while not in 
treatment. No difference 
between those initiated 
onto AOT in prison and 
those not.
4 year follow 
on RCT None
14.
AOT 
(METH 
and 
BUP)
Observa-
tional
AOT in (51%) of releases- 
AOT post-release 4 week 
CMR = (6.4 per 1000 PY, 
CI= 5.2- 7.8). 
No AOT CMR = (36.7 per 
1,000 PY CI= 28.8- 45.9) 
reduced by 75%. Short 
term protective factor.
No p 
value 
but sta-
tistically 
signifi-
cant.
Large –data 
linked
almost 100% 
follow up
Low risk- large 
population based 
study/good general-
izability
4.
BUP 
vs. 
no treat-
ment
RCT No reported deaths at 3 months follow up.
Descriptive- 
small study 
size
No effect
METH=methadone, BUP=buprenorphine, NLX=naloxone, NLT=naltrexone, 
LAAM= levo-alpha acetyl methadol
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relapse rates were significantly lower among the ex-
perimental group: 36% vs. 87% (p < 0.02) [44]. There 
was limited data available on other drug use both for 
self-report and drug screen. Kinlock et al. [38, 40] 
reported on cocaine use (drug screen and self-report) 
and found less cocaine use in the METH group vs. the 
control (45% vs. 65%); however this difference was 
not statistically significant. This was similar at three, 
six and 12 month follow-up. McKenzie et al. [56] also 
found reduced cocaine use in the METH group (19% 
vs. 67%) (p= 0.05). See Table 7. 
3.4.  Assessment of Quality
Quality was assessed as good in five studies [16, 
20, 28, 38, 53], adequate in six [37, 50, 51, 56, 71, 75] 
and inadequate in two [19, 26]. See Table 8. 
Selection bias: Randomisation: all included 
trials were described as randomised. Lee et al. [44] 
(RCT) was not included for risk of bias assessment 
since only data from an abstract was available for in-
clusion. Tables 8 and 9. Only in one of the RCTs [19] 
was the randomisation process not described (rated 
unclear). Two studies [53, 50] reported that the allo-
cation process was concealed (low risk). The remain-
ing five were rated as unclear. In six studies baseline 
data between the control and experimental data were 
comparable. In Kinlock et al., [37] group comparabil-
ity was unclear since many of those randomised to 
the experimental arm withdrew and were added to the 
control arm. Logistic regression analysis controlling 
for baseline between the group differences was used 
when testing outcome between groups.
Performance and detection bias: Blinding was 
assessed across four dimensions considering perfor-
mance and detection bias across subjective and ob-
jective measures. Six studies were rated as unclear as 
providing no information on blinding across all do-
mains. Lobmaier et al. [50] was considered high risk 
of bias for participant and performance blinding.
Attrition bias: Three of the seven studies dealt 
with incomplete data and were rated as low risk [20, 
28,38]. Magura et al. [53] was rated as unclear as 
the loss to follow up may have overstated treatment. 
Kinlock et al. [37] was rated as high risk as follow 
up groups were not comparable due to high attri-
tion, especially in the experimental group after ran-
domisation and before treatment. The original design 
was revised in this study and analysis controlled for 
baseline differences between the groups. Four of the 
studies included did not carry out intention-to-treat 
analysis [20, 28, 37, 53]. 
months (27% vs. 9%) (p<0.01). 
3,2,2, Non-fatal overdoses (NFOD)
This outcome was only reported in two of the 
included studies (Table 4). McKenzie et al. [56] re-
ported that 14% of those included in the study expe-
rienced NFODs on release and found that these were 
distributed evenly across those receiving METH on 
release and those in the referral for treatment group. 
Zaller et al. [75] showed that 8% of the study group 
reported at least one episode of NFODs post-release 
and all of these were not on BUP treatment at the time 
of release. On analysis this was not found to be statis-
tically significant (p=0.23). See Table 5. 
3.2.3. Overdose Mortality
This primary outcome was reported in six of 
the included studies. Kinlock et al. [38] reported one 
overdose death in the no treatment group in the first 
month post-release, and reported eight deaths at 12 
months. 50% of these deaths were overdose related 
and all occurred in the no treatment arm of the study 
[40]. The other deaths in this group were cardiovas-
cular and HIV related. The single death in the treat-
ment group was cardiovascular in nature. McKenzie 
et al. [56] reported two deaths immediately post-re-
lease in those not receiving METH. Dolan et al. [19] 
reported 17 deaths at four years follow up, none re-
ceiving METH at the time of their death and this was 
independent of having received METH at the time of 
release from prison. Degenhardt et al. [16] found a 
statistically significant difference in four week post-
release crude mortality ratio (CMR) between those on 
AOT and those not on AOT, with AOT reducing it by 
75% (AOT 4 week CMR= 6.4 per 1000 PY, CI=5.2-
7.8, no AOT CMR = 36.7 per 1000 PY, CI = 28.8-
45.9). See Table 6. 
3.3. Synthesis of Secondary Outcomes
3.3.1. Continued use of heroin and other illicit drugs 
Four studies reported on post-release hero-
in use in the METH vs. no METH group. These 
showed a significant reduction in heroin use both by 
drug screen and self-report at one month follow up 
(p<0.05) but this effect reduced over three, six and 12 
months and became statistically not significant (ns.) 
[20, 27, 38-40 51, 56]. Two studies showed differ-
ences in self-report heroin use for both BUP vs. no 
BUP or BUP vs. METH but these differences were 
not statistically significant [ 53,75]. For the NLT vs. 
no pharmacotherapy, four-week post-release opioid 
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3.4.1. Assessment of the Quality of Non-Randomised 
Trials
Quality assessment of the one non-randomised 
trial [75] was conducted using Transparent Report-
ing of Evaluations with Nonrandomized Designs 
(TREND). Zaller et al. [75] arose from a feasibility 
study with an experimental study occurring due to 
the non-availability of BUP for those enrolled in the 
early part of the study. Whilst not randomised, both 
Reporting bias: Unclear reporting of the meth-
odology was evident in six of the studies. Kinlock et 
al. [37] was assessed as high risk due to the extensive 
lack of information provided regarding those who 
dropped out. Of the original 145 randomly assigned 
only 64 were followed up, with 55% attrition in the 
experimental arm. 
Other potential sources of bias: All seven were 
rated high as regards other potential sources of bias. 
Table 7. Continued use of heroin and other illicit drugs
Ref Out-come Intervention Study type Outcome 
Positive 
outcome at p 
< 0.05
Comments 
Possible 
impact of bias 
on treatment 
effect (from 
on Table 4)
3.
Heroin 
Use - 
Drug 
Screen 
METH versus 
no treatment RCT
1 month Urine positive 
for morphine METH 
(28%) vs. control (41%) 
and (63%) 
3 months ,39%, 39%, 
48%, 
6 months 65%, 48%, 
28%, 
12 months odd ratio (OR) 
0.57 vs. 4.046 vs. 7.07 
P< 0.05
n.s.
P= 0.002
P<0.01 and 
P<0.001
Small size, 
loss to fol-
low up in 
non-treat-
ment group
None
1.
Heroin 
use – 
Self 
Report 
METH versus 
no treatment RCT
METH 0/12 re-addicted, 
10/12 intermittent, 2/12 
none vs. control 18/20 
re-addicted.
P= 0.008 Patient records underestimate
3.
One month experimen-
tal (40%) vs. (39%) and 
(60%), 
3 months (55%) vs. (60%) 
and (77%), 
6months (86) days vs. 49 
days, 
12 month (106.2) vs. ( 
120.7) vs. (167.1)
P< 0.02 
P= 0.014
P=0.009
underestimate
6.
(14%) of pre-release treat-
ment groups relapsed vs. 
(56%) and (44%)
P = 0.008 As treated n.s
7. BUP versus no treatment
Non-
randomised 
trial
None in the pre-release 
group, heroin 23.1% of 
the post-release group 
reported heroin use
P=0.08 Underestimate
4. BUP vs. METH RCT
Heroin or non prescribed 
opiate use: BUP (53%) 
vs. METH (66%)
n.s.
9 NLT vs. no treatment RCT
NLT vs. no AOT, 4 week 
follow up for opioid re-
lapse (36% ) vs.( 87%) 
p < 0.02
Preliminary 
findings on 
only 29 
unsure
3.
Other 
drugs 
– Drug 
Screen
METH versus 
no treatment RCT
One month for cocaine 
use 45% vs. (65%),
3 months (42%) vs. (39%) 
and (65%),
n.s.
n.s.
6. Other Drugs – Self Report RCT
Cocaine use at 6 months: 
control (19%) vs. (41%) 
and (67%)
P=0.05 underestimate
METH=methadone, BUP=buprenorphine, NLX=naloxone, NLT=naltrexone, 
LAAM= levo-alpha acetyl methadol
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other illicit drugs in the control group and the treat-
ment effect of BUP on these outcomes. See Table 9. 
3.4.2. Assessment of the Quality of Observational Stud-
ies
The quality of observational studies was as-
experimental and control groups were comparable at 
base line. The control arm was much larger than the 
experimental arm (32 vs.12) but had 25% attrition at 
six month follow up. While not impacting on the out-
come of treatment retention outcomes may have un-
derestimated NFODs and continued use of heroin and 
Table 8. Risk of Bias Assessment for RCTs
Ref. 
No. 
Sequence 
generation 
adequate
Allocation 
conceal-
ment
Baseline 
data/selec-
tion basis
Incomplete outcome data 
adequately addressed
Intent to 
treat analy-
sis
Other limitations dis-
cussed by authors
1.
Yes – al-
location by 
lottery
Risk = low
Unclear
Risk = 
unclear 
Groups com-
parable
Risk = low 
Yes – no missing data on 
outcomes.
Risk = low
No
Small sample size, no 
urine drug screens avail-
able on controls.
Risk = high 
2.
Unclear
Risk = 
unclear 
Unclear 
Risk = 
unclear
Unclear: 
baseline data 
only given 
for follow up 
group
Risk = un-
clear 
Follow up group’s not 
comparable, high drop out 
by experimental group 
post-randomisation and pre 
treatment. Study design 
revised to include this. Those 
who withdrew before treat-
ment were allocated to the 
experimental group. Analy-
sis controlled for baseline 
difference.
Risk = low
No
Small sample, males 
only, one site and urine 
drug screens and treat-
ment records only avail-
able for the experimental 
arm.
Risk = high
3.
Yes - block 
randomisa-
tion
Risk = low
Unclear
Risk = 
unclear
Groups com-
parable
Risk = low
Yes –high follow up rates for 
all groups.
Risk = low
Yes
Male only, one jurisdic-
tion.
Risk = high
4.
Yes- block 
randomisa-
tion
Risk = low
Yes- al-
location 
process was 
concealed
Risk = low 
Groups com-
parable
Risk = low
Significant pretreatment drop 
out in the control group and 
in post-release follow up. 
Risk = high
Yes
High dropout rates in 
METH group, small 
number of participants, 
urine drug screens not 
available, large amount 
of inmates chose not to 
be considered for the 
trial.
Risk = high
5.
Yes – 
random 
number 
generator
Risk = low
No 
Risk = high
Groups com-
parable
Risk = low
Unclear – loss to follow 
up may overstate treatment 
effect- likely to similar for 
experimental and control 
arm.
Risk = unclear
Yes
Male only, one site, and 
suboptimum doses of 
METH.
Risk = high
6.
Yes-com-
puter gener-
ated random 
permutation
Risk = low
Unclear
Risk = 
unclear
Groups com-
parable
Risk = low
70% follow up at 6 months, 
no significant differences 
found between follow up 
groups
Risk = high
Yes
Self report for drug use, 
standard of care changed 
mid-study with two of 
the control arms becom-
ing one, restrictive inclu-
sion criteria.
Risk = high
8.
Yes – block 
randomisa-
tion
Risk = low
Unclear
Risk = 
unclear
Groups com-
parable
Risk = low
95 % follow up post-release 
Risk = low No
Single location-reduced 
generalizability/restric-
tive exclusion criteria/
small numbers of female 
prisoners/geographical 
barriers to accessing 
community treatment not 
addressed
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those who dropped out at the allocation phase. In 
the observational studies systematic bias may have 
occurred if those receiving the pharmacological in-
terventions had more severe dependence than those 
not receiving the intervention and may then under-
estimate the effect of the pharmacotherapy cumula-
tively across the studies. This may have occurred on 
three of the included observational studies, since no 
description is included on the baseline difference be-
tween cohort and controls [16, 26, 51]. The differ-
ence in variables such as age, HIV status and history 
of mental illness may also have impacted negatively 
on outcomes. For both experimental and observa-
sessed using a checklist of preferred reporting items 
for systematic reviews (PRISMA statement) [45]. See 
Table 10.
3.4.3. Bias across Studies
The inclusion of randomised, non-randomised 
and observational studies made the assessment of bias 
across the studies difficult. Bias across the included 
experimental studies arose mainly from: treatment 
dropout post-randomisation and allocation, failure to 
describe the methodology for the blinding of outcome 
assessor and the management of incomplete data and 
dropout both from participants and, particularly, from 
Table 9. Risk of Bias for Non Randomised Trials
Ref. 
No.
Sequence 
generation 
adequate
Allocation con-
cealment
Baseline data/
selection basis
Incomplete outcome 
data adequately ad-
dressed
Intent 
to treat 
analysis
Other limitations 
discussed by au-
thors
7.
No – arose 
from feasibil-
ity study
No Groups compa-rable 
82% follow up at 6 
months. More loss to 
follow up in referral 
group. No analysis done 
on loss to follow up 
group.
No
Small sample size, 
no data on those 
who refused to 
participate, single 
site, reliance on self 
report for drug use.
Risk =high Risk = unclear Risk = low Risk = unclear Risk = high Risk = high
Table 10. Quality of Observational Studies
Ref 
No. 
Meth-
odol-
ogy ex-
plained 
Inclu-
sion 
criteria 
de-
scribed
Vari-
ables 
defined
Number 
of indi-
viduals 
at each 
stage 
reported/
descrip-
tive data 
Main 
results 
clearly 
pre-
sented 
Follow up 
rate
Limitations/bias dis-
cussed by authors
Evaluation of bias/limita-
tions 
10. Yes Yes Yes Yes Yes
AOT = 
67% 
Detox = 
47%
Pre–study differ-
ences between 
groups and controls 
(adjusted for statisti-
cally), loss to follow 
up bias, poor records 
for community fol-
low up group.
Non response bias (no im-
portant base line differences 
in interviewed versus not 
interviewed; lower treat-
ment contact rates for not 
interviewed) may understate 
treatment effect. 
11. Yes Yes Yes Yes Yes Mortality 100%
No data available for 
drug use.
Study is a follow up study 
of almost 4 years, so doesn't 
reflect the effect of post-re-
lease from pharmacotherapy. 
12. Yes Yes Yes Yes Yes Overall 93%
Feasibility rather 
than outcome study, 
no control group, 
small sample size, 
short follow up.
Selection bias: significant 
pre-incarceration differences 
between groups, higher 
levels of heroin use and 
injecting in those completing 
treatment
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limit the studies’ ability to assess differences between 
the study groups. 
4. Discussion
The review investigated effectiveness of com-
monly used pharmacotherapies in treating opioid de-
pendence in prisons in relation to treatment retention, 
levels of NFODs and mortality rates; and continued 
heroin and other illicit drug use in different post-re-
lease timeframes. Factors complicating the interpre-
tation of the effectiveness of pharmacotherapy inter-
ventions and their impact on post-release overdose 
mortality centre on the wide regional differences in 
post-release overdose rates which are accounted for 
by difference in prison populations studied, loss of 
follow-up, local variation in heroin purity, region-
al variation in drug injecting versus non-injecting 
routes, regional difference in poly-drug use (particu-
larly benzodiazepines and alcohol), differences in 
availability and type of community treatment. 
Limitations of the review centred on the follow-
ing. Most studies included in this systematic review 
had small numbers, excluded female prisoners and 
those with a history of major mental illness. Most 
tional studies, the small numbers of female prisoners, 
the exclusion of prisoners with severe mental health 
problems, the unique post-release arrangements and 
the preponderance of studies from the USA reduces 
their generalizability to other jurisdictions and the 
general prisoner population. 
Loss to follow up is a major problem in prison-
based research where post-release outcomes are be-
ing researched. Losses to follow-up tend to have more 
negative outcomes than those who are followed-up 
and this may impact on findings. The primary out-
comes of retention in treatment or post-release mor-
tality (if national death register is used) should not be 
affected by loss to follow-up but all other outcomes 
may be affected. The use of intention-to-treat analysis 
in RCTs reduces this potential source of bias but may 
negatively affect some outcomes if the assumption 
is made that those lost to follow-up have relapsed. 
Failure to conduct intention-to-treat analysis could 
underestimate the treatment effect. Response bias of 
self-reported data (due to social acceptability) is also 
possible for the primary outcome of NFODs and the 
secondary outcome of continued use of heroin and 
other illicit drugs. The small sample size in all the 
RCTs and in most of the observational studies may 
Table 10. Quality of Observational Studies
Ref 
No. 
Meth-
odol-
ogy ex-
plained 
Inclu-
sion 
criteria 
de-
scribed
Vari-
ables 
defined
Number 
of indi-
viduals 
at each 
stage 
reported/
descrip-
tive data 
Main 
results 
clearly 
pre-
sented 
Follow up 
rate
Limitations/bias dis-
cussed by authors
Evaluation of bias/limita-
tions 
13. Yes Yes Yes Yes Yes
Not rel-
evant 
Only 
looking at 
treatment 
retention.
Small sample size, 
male only, one site.
Very restrictive entry criteria 
limiting its generalizability. 
No analysis of difference 
between groups which may 
have affected both dose and 
retention outcomes.
14. Yes Yes Yes Yes Yes 100%
Inconsistencies 
may arise from data 
linkage process 
because two different 
agencies involved, 
unable to indentify 
unexpected releases 
that may have been 
released without a 
prescription, unable 
to determine differ-
ences in character-
istics between those 
entering/not entering 
AOT post-release.
Very large data linkage study 
with almost 100% follow up, 
very low risk of bias related 
to mortality outcome. No 
randomisation bias since 
entire population included. 
High generalizability.
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full supervision of medication. Release from prison is 
a stressful and busy period for the former inmate and 
daily attendance for pharmacotherapy is one of many 
competing needs and one which is difficult to main-
tain [43]. Attempted diversion of BUP among prison-
ers while incarcerated was reported in one study [28] 
and is a weakness in the widespread use of this medi-
cation as a prison based AOT. The success of both 
LAAM and BUP in treatment retention increase AOT 
options for pre-release treatment [37, 28, 53]. The 
long-acting nature of LAAM gives a further 24-48 
hour time frame for patients to engage with commu-
nity services before experiencing withdrawal. Given 
the increasing concerns related to METH's effect on 
the QT interval and the increased risk assessment and 
cardiac evaluation of patients before starting METH 
replacement treatment (MRT), it may be timely to 
review the utility of this forgotten AOT. The ability 
to double-dose prisoners with BUP could be utilised 
to extend the timeframe (48 hours) for prisoners to 
attend community AOT services which may have a 
further positive impact on treatment retention. The 
impact of requiring medical insurance for on-going 
treatment is a factor addressed in a number of the US 
studies [28, 75]. It is noted that this is not an issue in 
Europe or Australia where drug treatment services are 
largely publicly funded.
In terms of additional therapeutic supports, the 
recent development of long-acting NLT formulations 
is an exciting option in the use of antagonist phar-
macotherapy in pre-release prisoners, particularly for 
those who choose to undergo detoxification and wish 
to remain drug abstinent on release. NLT achieved 
higher treatment retention than METH at six months 
follow up (70% vs. 24%) (p=0.003) and is showing a 
promising reduction in one month post-release drug 
use when compared to no pharmacotherapy in pre-
liminary results from a recently completed RCT [ 
44]. While these results are promising, NLT should be 
used in a context of augmenting existing AOT services 
and not as an alternative. Patient choice had a major 
impact on acceptance of this treatment option [50].
The pharmacodynamics of the slow-release formula-
tion ensures treatment retention and overdose protec-
tion for the duration of its effectiveness (3-6 months) 
but delayed treatment fallout and overdose can occur 
once its antagonist effect wears off [10,17]. The long-
acting formulations allow for immediate protection in 
the early post-release phase and for a comprehensive 
community-based relapse prevention programme to 
be put in place, which may also include continuation 
of NLT therapy. 
had limited geographical variation (the majority 
were USA based) and they did not evaluate the ef-
fect the transfer of care process itself or community 
treatment had on the studies’ outcomes. Most of the 
included studies had important methodological short-
comings. Given the difficulties in conducting experi-
mental studies in the prison population, particularly 
when community follow-up is required, the inclu-
sion of both experimental and observational studies 
increased the available evidence to draw conclusions 
from, but limited the synthesis of data on outcomes. 
The inclusion of observational studies significantly 
increased the population of prisoners included in the 
systematic review. The synthesis of data was also 
impeded by the heterogeneity of the included stud-
ies and the unique design of many of the RCTs even 
made synthesis across RCTs difficult. A notable limi-
tation of this review is that only one study compared 
different types of AOT therapies [53]. The increasing 
evidence for the effectiveness of AOT in prison, on re-
lease and in the community makes it increasingly dif-
ficult to conduct prison-based RCTs which, by their 
design, involve withholding treatment to a cohort 
which fit the criteria for AOT. The limited use and the 
lack of research in prison populations for both NLT 
and NLX, mean that these could still be considered 
experimental or novel approaches to opioid depend-
ence treatment in pre-release prisoners, particularly 
for those who wish to be drug-free on release or those 
with a history of injecting. 
Findings underscore that AOT (METH, BUP, 
LAAM) initiated pre-release was associated with sig-
nificant post-release treatment retention on discharge 
into the community, and post-release reduction in 
heroin use. Unfortunately no study compared AOT 
for the period of incarceration with AOT initiated pre-
release. Prisoners on AOT at release were more likely 
to attend community treatment compared to prisoners 
not on AOT but with a referral to community treat-
ment organised post-release [20, 53]. This improved 
retention was shown immediately post-release and 
was retained at one month, three months, six months 
and twelve months [27, 39, 40]. All of the agonist 
pharmacotherapies reviewed showed similar results 
for improved retention when compared to no AOT 
on release but, interestingly, prisoners released on 
BUP reported to their designated post-release com-
munity placement significantly more often than those 
on METH [53]. These differences could be explained 
by the less restrictive and flexible community-based 
BUP programmes compared with highly regulated 
METH programmes requiring daily attendance and 
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is also a strong argument for the continuation of AOT 
in prison. Given the heterogeneity of the prison popu-
lation and their complex medical and social needs, 
different pharmacotherapies may be more effective 
in different prisoner groups and those with a higher 
risk of overdose (mental illness, previous suicide at-
tempts, history of drug use, female prisoners) may 
require different approaches to treatment provision. 
Further research is warranted. 
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